IP Library › Granted Patent US 12,065,394
Granted Patent B2
US 12,065,394 · App. 17/041,960 · Granted Aug 20, 2024

Compound and pharmaceutical composition for preventing or treating obesity or metabolic syndrome comprising thereof

Inventors: Yong Tae Kwon (Seoul, KR); Srinivasrao Ganipisetti (Seoul, KR); Ki Woon Sung (Seoul, KR); Eui Jung Jung (Seoul, KR); Tae Hyun Bae (Seoul, KR); Su Ran Mun (Seoul, KR); Chan Hoon Jung (Seoul, KR)
Assignee: Seoul National University R&DBFoundation
C07C215/50A61P3/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,065,394
App. No.
17/041,960
Granted
Aug 20, 2024
Kind
B2
Abstract

The present invention provides a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof which can be effectively used for preventing or treating obesity or metabolic syndrome, and a pharmaceutical composition comprising the same. in Chemical Formula 1, R 1 and R 2 are the same as defined in the specification.

Claims (29)

1. A compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof,

in Chemical Formula 1,

R 1 is -L 1 -(phenyl),

R 2 is hydrogen, or -L 2 -(phenyl),

L 1 is C 1-5 alkylene, and

L 2 is C 1-5 alkylene,

with the proviso that not both R 1 and R 2 are benzyl.

2. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein

L 1 is —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 CH 2 CH 2 CH 2 —.

3. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein

L 2 is —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 CH 2 CH 2 CH 2 —.

4. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein

R 1 is —CH 2 -(phenyl), and

R 2 is hydrogen, —CH 2 CH 2 -(phenyl), —CH 2 CH 2 CH 2 -(phenyl), or —CH 2 CH 2 CH 2 CH 2 -(phenyl).

5. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein

R 1 and R 2 are equal to each other.

6. The compound or a pharmaceutically acceptable salt thereof according to claim 5 , wherein

R 1 and R 2 are —CH 2 CH 2 -(phenyl), —CH 2 CH 2 CH 2 -(phenyl), or —CH 2 CH 2 CH 2 CH 2 -(phenyl).

7. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein

the compound is any one selected from the group consisting of:

1) 2-(3,4-diphenethoxybenzylamino)ethanol,

2) 2-(3,4-bis(3-phenylpropoxy)benzylamino)ethanol,

3) 2-(3,4-bis(4-phenylbutoxy)benzylamino)ethanol,

4) 2-(benzyloxy)-5-((2-hydroxyethylamino)methyl)phenol,

5) 2-(4-(benzyloxy)-3-phenethoxybenzylamino)ethanol,

6) 2-(4-(benzyloxy)-3-(3-phenylpropoxy)benzylamino)ethanol, and

7) 2-(4-(benzyloxy)-3-(4-phenylbutoxy)benzylamino)ethanol.

8. A method for preventing or treating obesity or metabolic syndrome in a subject in need thereof, comprising administering to the subject the compound or a pharmaceutically acceptable salt thereof according to claim 1 .

9. The method according to claim 8 , wherein the metabolic syndrome is any one selected from the group consisting of myocardial infarction, arteriosclerosis, hyperlipidemia, hypertension, cerebral infarction, cerebral hemorrhage, fatty liver, and type 2 diabetes mellitus.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2024
From: PROTECH CO., LTD.
To: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Reel/Frame 066498/0282 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2023
From: KWON, YONG TAE; SUNG, KI WOON; JUNG, EUI JUNG; BAE, TAE HYUN; MUN, SU RAN; JUNG, CHAN HOON; GANIPISETTI, SRINIVASRAO
To: PROTECH CO., LTD.
Reel/Frame 063105/0512 →
Continuity (2)
Provisional Application 62648381 · Mar 26, 2018
Related Publication 20210024454A1 · Jan 28, 2021